Nucleoside diphosphate kinase B is an enzyme that in humans is encoded by the NME2 gene. [5][6] Nucleoside diphosphate kinase (NDK) exists as a hexamer composed of 'A' (encoded by NME1) and 'B' (encoded by this gene) isoforms. Multiple alternatively spliced transcript variants encoding the same isoform have been found for this gene.

来自邻近上游基因 (NME1) 的通读转录生成天然存在的转录本 (NME1-NME2) ，该转录本编码一种融合蛋白，该融合蛋白由与每个单独基因产物共享同一性的序列组成。 [RefSeq 提供，2010 年 11 月] Nucleoside diphosphate kinase (NDK) exists as a hexamer composed of 'A' (encoded by NME1) and 'B' (encoded by this gene) isoforms. Multiple alternatively spliced transcript variants have been found for this gene.

2018年6月13日 · NME Radio consists of two channels – NME 1 and NME 2 – curating the best tracks from the indie and alternative worlds, as well as leftfield dance, grime, hip hop and everything in between. New...

Results: We found that Nme 2 Cas9 made efficient editing in target genes up to 71.8% post 11 days in vivo. And only Nme 2 Cas9-Vegfa treatment during the early stage of CNV development reduced the CNV lesion area by 49.5%, compared to the negative control, while Nme 2 Cas9-Hif1α or Nme 2 Cas9-Vegfr2 treatment did not show therapeutic effect.

2024年12月25日 · NME2 (NME/NM23 Nucleoside Diphosphate Kinase 2) is a Protein Coding gene. Diseases associated with NME2 include Nemaline Myopathy 2 and Burkitt Lymphoma. Among its related pathways are Pyrimidine metabolism and Metabolism of nucleotides.

NME2 Is a Master Suppressor of Apoptosis in Gastric Cancer Cells via Transcriptional Regulation of miR-100 and Other Survival Factors.

Listen to NME 2 live. The best UK radio stations. Free radio online at radio-uk.co.uk.

2018年6月13日 · NME has officially launched not one but two new audio channels: NME 1 and NME 2. Broadcasting 24/7, they bring you the best in brand new tunes and stone cold classics around the clock.

nme2 和 c-myc mRNA 的水平通过实时定量 PCR 确定。结果：全长 NmE2 蛋白和 5 个测试的 HLA-A2 锚定肽中的 2 个（NmE2132-140 和 NmE2112-120）被 HLA-A2+ CD8+ MLLC 特异性识别，证明了 NmE2 在体外 HLA-A2 背景中的抗原性。

NME 2 (BMS)，由Bristol Myers Squibb Co. (Bristol Myers Squibb Co.)公司最早进行研发，目前全球最高研发状态为临床1期，治疗领域: 免疫系统疾病，在研适应症: 自身免疫性疾病，在研机构: Bristol Myers Squibb Co.。